Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FEVEX: Fulvestrant vs Everolimus/Exemestane Sequencing in Breast Cancer
NCT02404051Phase 3Unknown
- Sponsor
- Consorzio Oncotech
- Start
- Dec 2015
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of everolimus in breast cancer, sponsored by Consorzio Oncotech. Status: unknown.
02
Drugs
everolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02404051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02404051.